Literature DB >> 31201862

Slow graded reintroduction of oxcarbazepine for delayed maculopapular eruption.

Christine R F Rukasin1, Elizabeth J Phillips2, Allison E Norton3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31201862      PMCID： PMC6778716          DOI： 10.1016/j.anai.2019.06.001

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN： 1081-1206            Impact factor:   6.347


× No keyword cloud information.
  10 in total

1.  HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.

Authors:  Mark McCormack; Ana Alfirevic; Stephane Bourgeois; John J Farrell; Dalia Kasperavičiūtė; Mary Carrington; Graeme J Sills; Tony Marson; Xiaoming Jia; Paul I W de Bakker; Krishna Chinthapalli; Mariam Molokhia; Michael R Johnson; Gerard D O'Connor; Elijah Chaila; Saud Alhusaini; Kevin V Shianna; Rodney A Radtke; Erin L Heinzen; Nicole Walley; Massimo Pandolfo; Werner Pichler; B Kevin Park; Chantal Depondt; Sanjay M Sisodiya; David B Goldstein; Panos Deloukas; Norman Delanty; Gianpiero L Cavalleri; Munir Pirmohamed
Journal:  N Engl J Med       Date:  2011-03-24       Impact factor: 91.245

2.  A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions.

Authors:  Y-T Lin; Y-C Chang; R C-Y Hui; C-H Yang; H-C Ho; S-I Hung; W-H Chung
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-01-03       Impact factor: 6.166

3.  The Frequency and Clinical Features of Hypersensitivity Reactions to Antiepileptic Drugs in Children: A Prospective Study.

Authors:  Hakan Guvenir; Emine Dibek Misirlioglu; Ersoy Civelek; Muge Toyran; Betul Buyuktiryaki; Tayfur Ginis; Murat Capanoglu; Esra Gurkas; Alev Guven; Can Naci Kocabas
Journal:  J Allergy Clin Immunol Pract       Date:  2018-03-06

4.  HLA-B*40:02 and DRB1*04:03 are risk factors for oxcarbazepine-induced maculopapular eruption.

Authors:  Jangsup Moon; Tae-Joon Kim; Jung-Ah Lim; Jun-Sang Sunwoo; Jung-Ick Byun; Soon-Tae Lee; Keun-Hwa Jung; Kyung-Il Park; Ki-Young Jung; Daejong Jeon; Kyung-Sang Yu; In-Jin Jang; Kon Chu; Sang Kun Lee
Journal:  Epilepsia       Date:  2016-09-26       Impact factor: 5.864

5.  Successful desensitization to fixed drug eruption: the presence of CD25+CD4+ T cells in the epidermis of fixed drug eruption lesions may be involved in the induction of desensitization.

Authors:  Yuichi Teraki; Tetsuo Shiohara
Journal:  Dermatology       Date:  2004       Impact factor: 5.366

Review 6.  Phenotypes, genotypes, and the management of paroxysmal movement disorders.

Authors:  Laura Silveira-Moriyama; Stjepana Kovac; Manju A Kurian; Henry Houlden; Andrew J Lees; Matthew C Walker; Emmanuel Roze; Alex R Paciorkowski; Jonathan W Mink; Thomas T Warner
Journal:  Dev Med Child Neurol       Date:  2018-03-30       Impact factor: 5.449

7.  HLA-A*31:01 and Oxcarbazepine-Induced DRESS in a Patient With Seizures and Complete DCX Deletion.

Authors:  Hyun Kim; Laura Chadwick; Yasir Alzaidi; Jonathan Picker; Annapurna Poduri; Shannon Manzi
Journal:  Pediatrics       Date:  2018-04       Impact factor: 7.124

8.  Human leukocyte antigen genotypes and trial of desensitization in patients with oxcarbazepine-induced skin rash: a pilot study.

Authors:  Bolyun Lee; Hee Joon Yu; Eun-Suk Kang; Munhyang Lee; Jeehun Lee
Journal:  Pediatr Neurol       Date:  2014-03-27       Impact factor: 3.372

Review 9.  Hypersensitivity Reactions to Antiepileptic Drugs in Children: Epidemiologic, Pathogenetic, Clinical, and Diagnostic Aspects.

Authors:  Semanur Kuyucu; Jean-Christoph Caubet
Journal:  J Allergy Clin Immunol Pract       Date:  2018-08-10

10.  Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.

Authors:  Elizabeth J Phillips; Chonlaphat Sukasem; Michelle Whirl-Carrillo; Daniel J Müller; Henry M Dunnenberger; Wasun Chantratita; Barry Goldspiel; Yuan-Tsong Chen; Bruce C Carleton; Alfred L George; Taisei Mushiroda; Teri Klein; Roseann S Gammal; Munir Pirmohamed
Journal:  Clin Pharmacol Ther       Date:  2018-02-02       Impact factor: 6.875
  10 in total
  2 in total

1.  Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go?

Authors:  Rannakoe J Lehloenya; Jonny G Peter; Ana Copascu; Jason A Trubiano; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2020-10

2.  Reintroduction of oxcarbazepine after allergic reaction in two pediatric patients with epilepsy.

Authors:  Lingyan Yu; Zhiliang Wang; Zhenwei Yu; Jianhua Feng; Haibin Dai
Journal:  Ann Clin Transl Neurol       Date:  2021-06-28       Impact factor: 4.511
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.